Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Tdf-Hiv'
Tdf-Hiv published presentations and documents on DocSlides.
Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials
by luanne-stotts
Progressive rises in weight and clinical obesity ...
Raltegravir + Darunavir/r versus TDF-FTC + Darunavir/r RADAR Trial
by keanu817
RADAR Trial. Raltegravir. + Darunavir/r versus TD...
Switch from Efavirenz + ZDV-3TC to Efavirenz + TDF-FTC
by ramon803
SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEE...
Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV
by kylo
Andrew Hill, Francois Venter, Eric . Delaporte. , ...
Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2)
by zane419
Study 105. Atazanavir + [Cobicistat or Ritonavir] ...
Switch to DOR-TDF-3TC vs. Continued Baseline Regimen
by dorothy
DRIVE SHIFT. Switch to Doravirine-TDF-3TC versus C...
Switching to TDF-FTC from ABC-3TC for Hyperlipidemia
by trinity
ROCKET II. Switching to TDF-FTC from ABC-3TC . for...
EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF)
by tawny-fly
M Harris, . S Guillemi. , K Chan, B Yip. ,. . M ...
Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial
by matthew167
NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir ...
Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112
by micah
Tenofovir. . Disoproxil. . Fumarate. to . Tenof...
Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial
by ricardo
ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-T...
EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC
by felicity
ACTG 5202. EFV versus ATV/r, both with ABC-3TC or ...
Retirement Plan Consulting
by oconnor
Overview of Services. Table of Contents. About RPA...
Total Soluble and Insoluble Dietary Fibre Contents of Wild Growing E
by alyssa
302 Vol. 32, 2014, No. 3: 302–307Czech J. Fo...
Renal and Bone Safety of
by ashley
Tenofovir. . Alafenamide. . vs. . Tenofovir. ....
Target Date Funds and P
by unita
lan . S. ponsor Responsibilities. Marcia S. Wagner...
Selecting an Initial Antiretroviral Therapy (ART) Regimen
by cappi
www.hivguidelines.org. Purpose of . This Guideline...
WHO ARV Forecasting Meeting
by sistertive
Geneva, March 19 - 20 , 2015 1 | Treatment and C...
Evolving Options for HBV Therapy:
by desiron
Navigating the New Treatment Landscape. Outline. I...
Joel E. Gallant, MD, MPH
by mastervisa
Medical Director, Specialty . Services. Southwest ...
Common Pharmacomistakes in Advanced Illness
by tawny-fly
Common Pharmacomistakes in Advanced Illness Opioi...
Comparative effectiveness of first-line antiretroviral therapy regimens: results from a large real-
by min-jolicoeur
implementation of Dolutegravir. Meireles MV. , Pa...
Florida AIDS Drug Assistance
by liane-varnes
Program. Improving Health. . . Promoting Wellness...
Tyre Stewardship in Canada
by sherrill-nordquist
Presented to . New Zealand . Tyre. Industry Summ...
P1084s: Impact of maternal
by olivia-moreira
tenofovir. . disoproxil. . fumarate. (TDF) . u...
ID Week Review 2015
by briana-ranney
Brian R. Wood, MD. Assistant Professor of Medicin...
Switch to DRV/r + RAL
by debby-jeon
SPARE . Study. SPARE Study: switch to DRV/r + RAL...
HBV resistance and
by calandra-battersby
immune escape . mutants. Anders Boyd, MPH, . PhD....
1 Adam O’Neill Leonid
by celsa-spraggs
Reyzin. Boston University. . A Unified Approach ...
Schéma
by tatiana-dople
de . l’étude. Critère. principal . –. pu...
Novel Antiretroviral Studies and Strategies
by danya
Bob Harrington, MD. University of Washington . Pre...
HEPATITIS B PART 2 DR MEERA G KOOTTUM;
by jacey
. TODAY. DIAGNOSIS. TREATMENT. SPECIAL SITUATIONS....
Introduction Characteristics, Treatment Patterns,
by cappi
and . Virologic. Outcomes . for Treatment-experie...
218RidruejoEAntiviraltreatmentforchronichepatitisBinrenaltransplant
by rose
jhep.2017.05.008 ,inpress.[243]DurantelD,ZoulimF.N...
Viral hepatitis Best of ILC 2018
by roberts
About these slides. These slides provide highlight...
MMM Prof. Mirjana Menkovska
by luna
, . Ss.Cyril. and Methodius University, Skopje, M...
Clinical considerations for the
by helene
introduction . of . DTG. Nandita Sugandhi. ICAP at...
16b21718196brt7118520b6415191234567b2tn116fnr
by daisy
123453467b646tntb7t1175t423br18t573b515115b3 11815...
Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions
by genesantander
Guidelines for the Use of Antiretroviral Agents in...
Switch to NNRTI Switch to DOR/3TC/TDF
by ellena-manuel
DRIVE-SHIFT. . Study. . Design. Endpoints. Prim...
Load More...
![Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2)](https://thumbs.docslides.com/1058605/atazanavir-cobicistat-or-ritonavir-tdf-ftc-phase-2.jpg)
